Data from the Pediatric Epilepsy Learning Healthcare System suggest that a variety of factors—including age, preference, insurance, and demographics—affect physician selection of antiseizure medications, with little standardization among this population.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.
The associate clinical professor of neurology at OSU Wexner Medical Center discussed the state of interdisciplinary care for individuals with epilepsy, and how these care teams operate. [WATCH TIME: 2 minutes]
Data from the BUTTERFLY study of 36 children with Dravet syndrome have provided 12-month measurements of neurodevelopment, clinical status, quality of life, and executive function. Investigators expressed that these data will help inform future trial outcome measures.
Zachary Grinspan, MD, MS, a pediatric epilepsy specialist at Weill Cornell Medicine, in New York City, spoke about the analysis of large amounts of data on pediatric epilepsy at the 2022 American Epilepsy Society Annual Meeting.
The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation discussed the critical need to ensure the proper classification of seizures when enrolling patients in clinical trials. [WATCH TIME: 4 minutes]
The research director and staff scientist at Cleveland Clinic’s Epilepsy Center detailed the clinical pre- and post-surgery benefits patients with epilepsy get from MR fingerprinting. [WATCH TIME: 3 minutes]
The staff epileptologist at Cleveland Clinic’s Epilepsy Center discussed new untapped ways seizure apps could help patients with epilepsy. [WATCH TIME: 2 minutes]
The staff epileptologist at Cleveland Clinic’s Epilepsy Center detailed the benefits seizure apps provide for patients with epilepsy, as well as the barriers that limit them. [WATCH TIME: 3 minutes]
The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided an inside look at the ways MR fingerprinting can provide real-time clinical benefit for physicians and patient care.
The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed opportunities for MR fingerprinting to expand, both in the epilepsy field and in general neurology. [WATCH TIME 3 minutes]
The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided insight on her study presented at AES 2021, which showed that MR fingerprinting can differentiate focal cortical dysplasia from healthy tissue. [WATCH TIME: 4 minutes]
The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed why MR fingerprinting holds significant clinical potential in epilepsy and epilepsy-related disorders.
Darcy Krueger, MD, PhD, director, Tuberous Sclerosis Clinic, Cincinnati Children’s, discussed the idea behind swiftly treating tuberous sclerosis at infant stages using targeted therapeutic approaches.
The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided background on the momentum behind MR fingerprinting and its potential in epilepsy care. [WATCH TIME: 3 minutes]
The clinical psychologist at Cleveland Clinic discussed the process for successfully changing and tailoring different cognitive behavioral therapy approaches to treat various forms of seizures. [WATCH TIME: 3 minutes]
The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the thought behind STOPS2, a trial aimed at preventing or delaying seizure onset in tuberous sclerosis complex. [WATCH TIME: 3 minutes]
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, provided context on improving our use of current antiseizure medications as the top priority for patients with epilepsy. [WATCH TIME: 2 minutes]
The director of the epilepsy center at Cleveland Clinic Neurological Institute spoke on one of the studies he coauthored that were presented at AES 2021. [WATCH TIME: 4 minutes]
The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on promising drug developments for tuberous sclerosis complex and other notable priorities within the space.
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the need for specificity and artificial intelligence for patients with epilepsy. [WATCH TIME: 4 minutes]
Jessica Fesler, MD, MEd, staff epileptologist, Cleveland Clinic, offered insight on the future of seizure apps and how if improved, they could alter the treatment of patients with epilepsy.
The medical director of the Epilepsy program at the University of Toronto discussed her presentation at AES 2021 regarding the need to change how clinicians view and treat patients with developmental epileptic encephalopathies.
The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the phase 2 open-label study of ganaxolone in TSC and whether drug development remains the top priority for these patients. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute spoke on the latest advances with epilepsy surgery, as well as what still needs to be learned. [WATCH TIME: 5 minutes]
Leaders in the epilepsy space provided their thoughts on the most promising aspects, initial takeaways, and dominating conversations at the 2021 American Epilepsy Society annual meeting.
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed poignant presentations from the 2021 American Epilepsy Society Annual Meeting. [WATCH TIME: 7 minutes]
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed numerous presentations from AES 2021 that bolstered cenobamate’s known efficacy and safety profile. [WATCH TIME: 7 minutes]
Investigators suggest further studies to better determine is NPC had measurable benefits for patient quality of life.
